Tags

Type your tag names separated by a space and hit enter

Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
Thromb Haemost 2003; 90(1):92-100TH

Abstract

Decrease of fibrinolytic potential is considered to be a risk factor for arterial thrombosis. The recently described thrombin-activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis by cleaving of the C-terminal lysine residues from fibrin, thereby inhibiting tPA mediated plasminogen activation. The role of plasma TAFI antigen (Ag) levels and gene polymorphisms in arterial thrombosis is still not elucidated. In this prospective study, the association between plasma TAFI Ag levels and the TAFI gene polymorphisms, Ala147Thr, Thr325Ile and -438A/G, with refractory unstable angina pectoris (UAP) was determined. The study population consisted of 209 patients with UAP of whom 76 were refractory and 133 non-refractory to medical treatment. In the same study population the contribution of these polymorphisms to plasma TAFI Ag levels was determined. Plasma TAFI Ag levels were significantly higher in non-refractory patients compared to refractory patients (geometric mean 114.4 and 105.6 U/dl respectively, p=0.042). Plasma TAFI Ag levels in the lowest quartile resulted in a 2.6 fold (95% confidence interval 1.2-5.9) increased risk for refractory UAP compared to plasma TAFI Ag levels in the upper quartile. The three studied TAFI polymorphisms had an independent and additive effect on plasma TAFI Ag levels. However, no significant association between the individual TAFI polymorphisms and refractiveness was observed. In conclusion, in this study population plasma TAFI Ag levels are significantly correlated with refractiveness in patients with UAP. Furthermore, all three polymorphisms contribute independently to plasma TAFI Ag levels, but not to refractiveness.

Authors+Show Affiliations

Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12876631

Citation

Brouwers, Geert-Jan, et al. "Association Between Thrombin-activatable Fibrinolysis Inhibitor (TAFI) and Clinical Outcome in Patients With Unstable Angina Pectoris." Thrombosis and Haemostasis, vol. 90, no. 1, 2003, pp. 92-100.
Brouwers GJ, Leebeek FW, Tanck MW, et al. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost. 2003;90(1):92-100.
Brouwers, G. J., Leebeek, F. W., Tanck, M. W., Wouter Jukema, J., Kluft, C., & de Maat, M. P. (2003). Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thrombosis and Haemostasis, 90(1), pp. 92-100.
Brouwers GJ, et al. Association Between Thrombin-activatable Fibrinolysis Inhibitor (TAFI) and Clinical Outcome in Patients With Unstable Angina Pectoris. Thromb Haemost. 2003;90(1):92-100. PubMed PMID: 12876631.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. AU - Brouwers,Geert-Jan, AU - Leebeek,Frank W G, AU - Tanck,Michael W T, AU - Wouter Jukema,J, AU - Kluft,Cornelis, AU - de Maat,Moniek P M, PY - 2003/7/24/pubmed PY - 2004/4/20/medline PY - 2003/7/24/entrez SP - 92 EP - 100 JF - Thrombosis and haemostasis JO - Thromb. Haemost. VL - 90 IS - 1 N2 - Decrease of fibrinolytic potential is considered to be a risk factor for arterial thrombosis. The recently described thrombin-activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis by cleaving of the C-terminal lysine residues from fibrin, thereby inhibiting tPA mediated plasminogen activation. The role of plasma TAFI antigen (Ag) levels and gene polymorphisms in arterial thrombosis is still not elucidated. In this prospective study, the association between plasma TAFI Ag levels and the TAFI gene polymorphisms, Ala147Thr, Thr325Ile and -438A/G, with refractory unstable angina pectoris (UAP) was determined. The study population consisted of 209 patients with UAP of whom 76 were refractory and 133 non-refractory to medical treatment. In the same study population the contribution of these polymorphisms to plasma TAFI Ag levels was determined. Plasma TAFI Ag levels were significantly higher in non-refractory patients compared to refractory patients (geometric mean 114.4 and 105.6 U/dl respectively, p=0.042). Plasma TAFI Ag levels in the lowest quartile resulted in a 2.6 fold (95% confidence interval 1.2-5.9) increased risk for refractory UAP compared to plasma TAFI Ag levels in the upper quartile. The three studied TAFI polymorphisms had an independent and additive effect on plasma TAFI Ag levels. However, no significant association between the individual TAFI polymorphisms and refractiveness was observed. In conclusion, in this study population plasma TAFI Ag levels are significantly correlated with refractiveness in patients with UAP. Furthermore, all three polymorphisms contribute independently to plasma TAFI Ag levels, but not to refractiveness. SN - 0340-6245 UR - https://www.unboundmedicine.com/medline/citation/12876631/Association_between_thrombin_activatable_fibrinolysis_inhibitor__TAFI__and_clinical_outcome_in_patients_with_unstable_angina_pectoris_ L2 - https://www.lens.org/lens/search?q=citation_id:12876631 DB - PRIME DP - Unbound Medicine ER -